Okra (Abelmoschus esculentus (L.) Moench) is one of the most important medicinal plants for the treatment of diabetes. Flavonoids are one of the most significant components of okra and are responsible for their antioxidant, anti-inflammatory, and anti-diabetic effects. The aim of this research was to investigate the effect of okra extract on biochemical parameters and expression of protein tyrosine phosphatase 1B (PTP1B) and Peroxisome proliferator-activated receptors (PPARs) genes in a model of streptozotocin-induced diabetic male Wistar rat. Rats were given oral dosages of okra extract, (75% ethanolic extract) (200-400 mg/kg) for eight weeks. Our findings indicate that okra extract and quercetin therapy may lower blood glucose (BS), insulin, Triglyceride (TG), Cholesterol (Cho), and glucose transporter protein type-4 (GLUT4) levels. PTP1B and Peroxisome proliferator-activated receptor alpha (PPAR-α), which are important regulators of glucose and lipid homeostasis, are similarly inhibited by okra extract. According to the findings, okra extract also has antioxidant properties. Our results support the anti-hyperglycemic and hypolipidemic properties of okra extract. As a result, it appears to play a crucial role in controlling diabetes. PRACTICAL APPLICATIONS: In this paper, we show that flavonoids in okra may help diabetes by inhibiting the PTP1B and PPAR-pathways. This is significant because little research has been done on the impact of flavonoid chemicals in A. esculentus on the expression of PTP1B and PPAR using traditional methods of diabetes treatment. Many of today's essential drugs (e.g., atropine, ephedrine, tubocurarine, digoxin, and reserpine) have been developed by studding traditional treatments. Plant-derived medications are still used as a prototype by chemists in an effort to develop more effective and less risky treatments (e.g., morphine, taxol, physostigmine, quinidine, and emetine.
Keywords: A. esculentus; diabetes; flavonoid; hyperglycemia; total flavonoid content; total phenolic content.
© 2022 Wiley Periodicals LLC.